Top

Published in:

01-12-2020 | Public Health | Letter to the Editor

Revisiting the public health implications of the United States–Mexico– Canada agreement

Author: Tolulope Anthony Adekola

Published in: Globalization and Health | Issue 1/2020

Abstract

This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.

TRIPS-Plus refer to the extension of Intellectual property protection standards beyond the minimum requirements set by WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

Labonté R, Crosbie E, Gleeson D, McNamara C. USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health. Glob Health. 2019;15(1):1–15.CrossRef

United States Trade Represenatative. Agreement Between the United States of America, the United Mexican States, and Canada (Preamble). United States Trade Represenatative [Internet]. 2019; Available from: https://ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement/agreement-between.

Owoeye O, Olatunji O, Faturoti B. Patents and the trans-Pacific partnership: how TPP-style intellectual property standards may exacerbate the access to medicines problem in the east African community. Int trade J [internet]. 2017;00(00):1–22. Available from: https://doi.org/10.1080/08853908.2017.1386143.

Osborn BJE. Biologics lose protection as U . S . -Canada- Mexico trade agreement moves forward. 2019;2.

Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. PharmacoEconomics. 2018.

Trump PDJ. President Donald J. Trump’s United States- Mexico-Canada agreement delivers a historic win for American workers. 2020;.

Pusceddu P. Assessing access to medicines in preferential trade agreements: from the trans-Pacific partnership to the comprehensive and progressive agreement for trans-Pacific partnership. IIC Int rev intellect prop Compet law [internet]. 2018;49(9):1048–79. Available from: https://doi.org/10.1007/s40319-018-0758-3.

Title: Revisiting the public health implications of the United States–Mexico– Canada agreement
Author: Tolulope Anthony Adekola
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Public Health
Published in: Globalization and Health / Issue 1/2020
Electronic ISSN: 1744-8603
DOI: https://doi.org/10.1186/s12992-020-00579-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Revisiting the public health implications of the United States–Mexico– Canada agreement

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Bibliometric analysis of peer-reviewed literature on climate change and human health with an emphasis on infectious diseases

Increasing the public health voice in global decision-making on nutrition labelling

Physicians’ brain drain - a gravity model of migration flows

Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research

Developing monitoring and evaluation tools for event-based surveillance: experience from Vietnam

Challenges and recommendations for mental health providers during the COVID-19 pandemic: the experience of China’s First University-based mental health team